FDA Approves Rocket Pharma's KRESLADI: First Gene Therapy for LAD-I

KRESLADI's approval matters less for its commercial scale than for what it signals about the durability of lentiviral gene therapy as a manufacturing-grade platform. On March 26, 2026 — the exact PDUFA deadline — the FDA granted accelerated approval to Rocket Pharmaceuticals (NASDAQ: RCKT) for KRESLADI (marnetegragene autotemcel), making it the first approved gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I). The decision reverses a June 2024 Complete Response Letter issued over Chemistry, Manufacturing, and Controls deficiencies, and in doing so delivers a read-through for the entire class of ex vivo stem cell therapies that has been underpriced in competitive analysis.

The gene therapy market is structurally bifurcated: a small cohort of approved ultra-rare disease therapies generating limited direct revenue, and a larger pipeline of indications — sickle cell, hemophilia, Duchenne muscular dystrophy — where commercial scale is plausible. The global gene therapy market was valued at approximately $6.3 billion in 2023 and is projected to expand at a CAGR of roughly 20% through the end of the decade, according to industry estimates (independent verification of this figure was not possible at time of publication). Within this landscape, the lentiviral ex vivo HSC modification segment is dominated by a handful of developers: Rocket Pharmaceuticals, bluebird bio (whose Lyfgenia for sickle cell disease received FDA approval in December 2023), Orchard Therapeutics (acquired by Kyowa Kirin in 2023), and Mustang Bio. LAD-I itself affects approximately 1 per 1,000,000 people globally — a disease so rare that Jefferies analysts project KRESLADI may treat fewer than 10 patients per year in the United States. The commercial ceiling is real, and it is low.

The granular terms of the approval define both the opportunity and its constraints. KRESLADI is an autologous therapy: the patient's own hematopoietic stem cells are collected, genetically modified ex vivo using a lentiviral vector to introduce functional copies of the ITGB2 gene — which encodes the beta-2 integrin component CD18 — and then re-infused following myeloablative conditioning. A single infusion addresses the root cause of the disease by restoring CD18 and CD11a cell surface expression in neutrophils and other white blood cells. The accelerated approval is based on the surrogate endpoint of increased neutrophil CD18 and CD11a surface expression, not on long-term survival data alone. The pivotal Phase 1/2 trial (ClinicalTrials.gov: NCT03812263) reported 100% overall survival in all enrolled patients for at least one year post-treatment, with substantial decreases in significant infection incidence and observed improvements in skin lesion healing. Confirmation of full clinical benefit will depend on longer-term follow-up data and a post-marketing registry. Alongside the approval, the FDA granted Rocket a Rare Pediatric Disease Priority Review Voucher — an instrument that has traded on the secondary market between $80 million and $155 million and that Rocket has stated it intends to monetize.

The approval is happening now because of a specific convergence: Rocket resolved the manufacturing deficiencies that triggered the 2024 CRL, the FDA's CBER office has operationalized accelerated approval pathways for rare pediatric conditions using novel surrogate endpoints, and the RMAT designation — which KRESLADI held — creates structured FDA engagement that accelerates manufacturing dialogue. The 2024 rejection was not a clinical failure; it was a process failure. That distinction matters because it means the 2026 approval functions as a public manufacturing quality signal, not merely a clinical one. The closest structural precedent is bluebird bio's path with Zynteglo for beta-thalassemia, which navigated European withdrawal, U.S. resubmission, and eventual 2022 FDA approval — a multi-year remediation arc that ultimately validated the lentiviral platform rather than discrediting it. Rocket's two-year arc from CRL to approval follows a comparable pattern.

The competitive implications of KRESLADI's approval are concentrated in two layers. The first is direct: Rocket now holds the only approved gene therapy for LAD-I, faces no approved gene therapy competition in this specific indication, and will price accordingly in a market where bone marrow transplant — the current standard of care — carries, as CEO Gaurav Shah has noted, 'substantial morbidity, mortality, and cost, and may not be available in time for these children.' The second layer is structural and affects the broader lentiviral platform ecosystem. Bluebird bio and Orchard Therapeutics share the ex vivo HSC modification architecture with Rocket; a public CMC resolution of this type reduces the regulatory risk discount the market applies to their pipelines. The entity that faces the most direct displacement is the allogeneic bone marrow transplant infrastructure — specifically the donor registries and transplant centers that currently manage these patients — though given the sub-10 annual patient volume, the displacement is more symbolic than commercially disruptive. The PRV monetization, when it occurs, will shift pricing power marginally: the acquirer of the voucher gains an expedited review slot worth an estimated 12 months of development time, a resource with asymmetric value for any developer racing a competitor to approval.

Our read: KRESLADI is a platform proof point, not a revenue story, and the market is correct to price it that way — but the platform proof point is being underweighted in competitive analysis of the broader lentiviral HSC sector. The testable hypothesis is this: if Rocket's CMC resolution is generalizable — meaning if CBER's manufacturing feedback process for lentiviral therapies has become sufficiently standardized that a CRL no longer signals terminal risk — then the risk-adjusted valuations of bluebird bio's pipeline assets and Orchard's post-acquisition programs should re-rate upward over the next 12 months as that signal propagates through regulatory filings. The disconfirming signal would be a new CRL or clinical hold on a lentiviral platform product at a different developer, which would suggest the Rocket resolution was idiosyncratic rather than systemic. The RP-A501 Danon disease program is the cleaner near-term test of Rocket's own execution: Jefferies estimates a $500 million opportunity there, and the Phase 2 restart — expected in the first half of 2026 — will either confirm that Rocket has built durable manufacturing competence or reveal that the LAD-I CMC fix was program-specific.

Four signals deserve active monitoring by decision-makers tracking this space. First, Rocket's PRV sale announcement: the transaction price — expected within 6–12 months of approval — will calibrate the current market-clearing value of rare pediatric disease priority review slots and directly inform Rocket's cash runway ahead of RP-A501 Phase 2 spending; a sale below $80 million would signal a softer PRV market and tighter near-term financing conditions for the company. Second, the RP-A501 Phase 2 dosing update: Jefferies expects Rocket to resume dosing in H1 2026 following the FDA's August 2025 clinical hold lift; the first safety and preliminary efficacy readout from the recalibrated dose cohort is the next hard catalyst and will determine whether the Danon disease program can realistically anchor the $500 million opportunity thesis. Third, treatment center qualification announcements: KRESLADI requires specialized apheresis and ex vivo cell processing infrastructure; patient access in 2026 will be gated by the number of qualified U.S. treatment centers, not by approval status, and the pace of center qualification is a leading indicator of real-world uptake. Fourth, lentiviral platform regulatory filings at bluebird bio and Orchard Therapeutics: if either company's next BLA submission or FDA meeting briefing documents explicitly references improved CMC standardization in the post-KRESLADI regulatory environment, that confirms the platform read-through thesis and represents a material shift in the risk calculus for the broader lentiviral gene therapy sector.